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Abstract
Psoriasis is a chronic, incurable, auto-immune disorder
with cutaneous manifestations. New evidence on the
central role of the immune system in the pathogenesis of
psoriasis increasingly provides insight into pathogenic
steps that can be modulated to provide disease control.
Numerous biological therapies are in various stages of
clinical development, with expectation of providing en-
hanced safety and efficacy over currently available pso-
riasis therapies. Efalizumab, a recombinant humanized
monoclonal IgG1 antibody, is a novel targeted T-cell
modulator that inhibits multiple steps in the immune cas-
cade that result in the production and maintenance of
psoriatic plaques, including initial T-cell activation and
T-cell trafficking into sites of inflammation, including
psoriatic skin, with subsequent reactivation in these
sites. This article reviews the pharmacodynamic, phar-
macokinetic and clinical effects observed during phase I,
II and III efalizumab trials in patients with moderate to
severe chronic plaque psoriasis.
Copyright © 2004 S. Karger AG, Basel
Introduction
Psoriasis is characterized by keratinocyte hyperprolif-
eration, abnormal keratinocyte differentiation and inflam-
matory infiltration of the dermis and epidermis with a pre-
dominance of activated CD4+ (helper) and CD8+ (cyto-
toxic) T cells in the dermis and epidermis, respectively, of
lesional skin from psoriasis patients [1–3]. Evidence has
accumulated to support an involvement of the immune
system in keratinocyte dysfunction and the pathogenesis of
psoriasis. Immunosuppressive drugs such as cyclosporine
[4] and T-cell-selective immunosuppressive agents such as
monoclonal CD4 antibodies [5, 6] or the fusion toxin
DAB389IL-2 (denileukin diftitox) [7] improve the symp-
toms of psoriasis, and severe combined immunodeficient
mouse models have confirmed the involvement of acti-
vated T cells in the pathogenesis of psoriasis [8, 9].
This evolution of understanding psoriasis as a conse-
quence of skin-specific T-cell-mediated events initiated
the development of targeted interventions aimed at inhib-
iting T-cell function. This report provides an overview of
the role of T-cell interactions in the pathogenesis of pso-
riasis and describes the evidence for T-cell-specific im-
mune modulation in the mechanism of action of efalizu-
mab, a humanized monoclonal IgG1 antibody for the
treatment of patients with moderate to severe chronic
plaque psoriasis.
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Fig. 1. Key T-cell interactions in the pathogenesis of psoriasis. In
order to mediate the cellular changes in the dermis that lead to pso-
riasis, T cells first undergo 3 key interactions with other cell types.
Step 1: APCs must first be activated in the epidermis, where antigen
is internalized, enzymatically processed and presented on the APC
surface. Activated APCs then travel to the regional lymph nodes,
where they interact with naı¨ve T cells, resulting in T-cell activation.
Step 2: T-cell binding to venous endothelial cells occurs, followed by
trafficking into dermal and epidermal tissue. Step 3: T-cell reactiva-
tion by a second exposure to the specific antigen occurs in the dermis
or epidermis. This leads to release of pro-inflammatory cytokines
and other inflammatory mediators, which stimulate the increased
keratinocyte proliferation. While step 1 occurs only once, it is fol-
lowed by proliferation of the activated T cells, providing an amplifi-
cation of the process. Steps 2 and 3 occur in an iterative fashion,
causing the persistence of the disease.
T-Cell Interactions in the Pathogenesis of
Psoriasis
Current models of psoriasis pathogenesis attempt to
incorporate findings from immunological and pathologi-
cal studies of psoriasis into the classical T-cell activation
pathway and typically include 3 key steps: initial presen-
tation of T cells by antigen-presenting cells (APCs), with
T-cell activation in primary or secondary immune organs
such as the lymph nodes or tonsils1, and T-cell trafficking
to the skin, with T-cell reactivation therein (reviewed in
Krueger [10]; fig. 1). It is likely that several types of T
cells, including CD4+, CD8+ and natural killer T cells, are
important in psoriasis [11, 12]; however, the roles of
CD4+ and CD8+ T cells in psoriasis are better understood
and are discussed in more detail in this review.
1 Prinz JC, Vollmer S: The clonal T cell receptor rearrangements of psoriatic
skin lesions are present in the CLA-positive fraction of tonsillar T cells in pso-
riasis patients with streptococcal sore throat (abstract). J Eur Acad Dermatol
Venereol 2002;16:113.
T-Cell Activation
The psoriatic pathway is thought to begin with the
antigen-specific activation of naı¨ve T cells. For full T-cell
activation to occur, 2 signals are required. According to
current assumptions of psoriasis pathogenesis, APCs
(classified as Langerhans cells in the epidermis and der-
mal dendritic cells in the dermis) capture and process an
as yet unidentified psoriatic antigen for presentation to T
cells via major histocompatibility complexes (MHCs) on
the surface of the APC. The nature of this antigen(s) is
unknown. Although recent data suggest that lipids may be
involved [13, 14], it has been more commonly speculated
that endogenous keratinocyte-derived peptide antigens
may play a role [15, 16]. Generally, APCs migrate through
the lymphatic system to a skin-draining lymph node,
where the MHC/antigen complex on the APCs is recog-
nized by specific receptor complexes (TCRs) on naı¨ve
(CD45RA+) CD4+ T cells, which have not previously
encountered antigen [17]. While there are no data avail-
able regarding where psoriatic T cells are initially acti-
vated, it is presumed that the process of APC presentation
to the TCR occurs in a similar fashion. Naı¨ve T cells enter
the lymph nodes via human high endothelial venules,
Treatment of Psoriasis with Efalizumab:
Mechanisms of Action
Dermatology 2004;208:297–306 299
with leucocyte function-associated antigen 1 (LFA-1) and
intercellular adhesion molecule 1 (ICAM-1) serving as the
predominant adhesion molecules. The interaction of the
MHC/antigen complex with the TCR is not in itself suffi-
cient for T-cell activation and proliferation. A mandatory
second signal also requires the interactions of numerous
surface adhesion and costimulatory molecules on the T
cell and the APC to form an immunological synapse [18,
19]. Pairs of interacting molecules include LFA-1/ICAM-
1 (CD54), CD2/LFA-3 (CD58), CD40 ligand/CD40, and
CD28/B7 costimulatory molecules (CD80 and CD86) on
the T cell and APC, respectively [10, 18]. Blocking this
second signal prevents full T-cell activation.
Secondary Signals in T-Cell Activation
LFA-1, an adhesion molecule expressed by most leuco-
cytes, plays an important role in the initiation of an
immune response via formation of the immunological
synapse [19, 20]. TCRs sample MHC-peptide complexes
expressed on the surface of the APC [21]. Immediately
upon detection of the MHC-peptide complex, the TCR
activates a T-cell signal transduction cascade [19, 21].
However, the TCR needs a sufficiently long duration of
interaction with the APC to allow full activation through
the TCR. LFA-1 binds with ICAM-1, expressed on the
surface of the APC, forming a tight junction between the
TCR and the APC, in what is referred to as the immuno-
logical synapse (fig. 2) [21]. The immunological synapse,
stabilized by LFA-1/ICAM-1 interaction, allows sus-
tained TCR engagement and signalling, which are re-
quired for full T-cell activation and proliferation [19].
Full T-cell activation has been simulated using a lipid
bilayer with only MHC and ICAM-1, demonstrating the
central role of LFA-1 and ICAM-1 to T-cell activation
[19, 21].
T-Cell Trafficking
The activated/memory T cells proliferate, migrate out
of the lymph nodes and circulate through the blood
stream until their surface receptors recognize areas of
cutaneous inflammation, which are marked by high ex-
pression of P- and E-selectins, and of the chemokine
CCL27 on the endothelial cell surface [17, 22, 23]. The
interaction of cutaneous lymphocyte antigen and of the
chemokine receptor CCR10 on T cells with P- and E-
selectins and with the chemokine CCL27 causes the T cell
to roll along the surface of the endothelium, allowing cyto-
kines and/or other inflammatory molecules that are
present locally at the site of dermal inflammation to
induce the conformational change in markers such as
Fig. 2. Formation of the immunological synapse. Reprinted with
permission from Elsevier [van der Merwe PA, Barclay AN: Trends
Biochem Sci 1994;19:354–358], adapted by Malissen [21].
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LFA-1 on the surface of the T cell. Interactions of LFA-1
with ICAM-1, ICAM-2 and ICAM-3, which are up-regu-
lated on activated endothelium, mediate the tight adhe-
sion of the T cells to epithelial cells and facilitate the sub-
sequent flattening and trafficking of the activated CD4+
T cells from the circulation into the dermis (reviewed in
Bradley and Watson [24]). Following extravasation, the T
cell responds to chemotactic signals from inflammatory
cells at the site of inflammation.
T-Cell Reactivation
Once in the skin, the CD4+ T cells interact via the
TCR and MHC molecules with APCs (T-cell reactiva-
tion), become reactivated in an antigen-specific manner
[25, 26] and produce a Th1-like cytokine pattern that
includes IFN-Á and TNF-· but not IL-4 [27]. These cyto-
kines are considered to be important mediators of the
inflammatory and hyperproliferative changes of psoriatic
skin lesions. Furthermore, the activated CD4+ T cells
may assist in the activation of CD8+ T cells [28]. CD8+ T
cells are cytotoxic T lymphocytes that can kill target cells.
As with CD4+ T-cell activation, activation of CD8+ T
cells requires secondary costimulatory interactions in ad-
dition to interactions between TCR on the T cell and
MHC on the APC. The specific APCs for CD8+ T cells
are unknown but could be keratinocytes or dendritic cells,
or both [15]. CD4+ Th1 cells express CD40 ligand, which
interacts with CD40 on APCs, resulting in an increased
production of cytokines [28, 29] and up-regulation of co-
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Fig. 3. Efalizumab mechanisms of action.
Efalizumab inhibits adhesion of T cells to
other cell types by inhibiting the binding of
LFA-1 to ICAM-1. This mechanism of ac-
tion has a number of effects, depending on
the cell type, including inhibition of T-cell
activation, inhibition of T-cell trafficking
and extravasation, and inhibition of T-cell
interactions with tissue-specific cells. Blood Flow
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stimulatory molecules necessary for CD8+ T-cell activa-
tion [28, 30]. In particular, ICAM-1 synthesis is induced
by IFN-Á and TNF-· on epidermal keratinocytes [31],
which do not normally synthesize this ligand [32]. In addi-
tion to LFA-1/ICAM-1, several different costimulatory
ligand-receptor pairs may be involved in CD8+ T-cell
activation, including CD2/LFA-3 and very late antigen 4/
vascular cell adhesion molecule 1 on the T cell and APC,
respectively [12]. Activated CD8+ T cells exhibit a type 1
cytotoxic phenotype in psoriasis [1, 33] and release IL-2,
IFN-Á and TNF-·. The exact mechanisms by which acti-
vated T cells exert their effects to cause the psoriatic phe-
notype are unknown but could involve interactions of a
specific array of cytokines and/or growth factors released
by the T cells with the epidermal keratinocytes. Cytokines
produced by T-cell clones established from psoriatic skin
lesions in vitro may selectively enhance keratinocyte pro-
liferation, which is a hallmark of psoriatic skin lesions [34,
35]. Direct interactions of T cells with epidermal kerati-
nocytes may also be important in driving T-cell activa-
tion, in turn contributing to the psoriatic phenotype [15].
Additionally, it is hypothesized that while migrating into
the epidermis, CD8+ T cells could induce keratinocyte
injury, which in turn triggers keratinocyte hyperplasia as
part of an injury response similar to the wound repair
response [10].
Blockade of T-Cell Costimulation as a Therapeutic
Approach
Because of the important role of LFA-1/ICAM interac-
tions in mediating multiple T-cell processes, targeting
these interactions represents a rational approach to inhib-
iting the psoriasis disease process. Monoclonal antibodies
directed against LFA-1 or its ligands have been found to
inhibit T-cell activation in vitro [36], inhibit T-cell-
dependent T-cell responses [37, 38], inhibit lymphocyte
proliferation responses [39, 40], reduce lymphocyte traf-
ficking and homing [41, 42] and reduce adhesion of
T cells to endothelial cells in vitro [43]. One strategy to
inhibit LFA-1/ICAM interactions has been to develop
antibodies against CD11a, the ·-subunit of LFA-1.
Efalizumab: A T-Cell Modulator for the
Treatment of Psoriasis
Efalizumab is a humanized monoclonal IgG1 antibody
that binds with high specificity and affinity to CD11a (the
·-subunit of LFA-1) [44]. According to the mechanisms of
T-cell activation explained above, efalizumab targets pso-
riasis pathogenesis at multiple levels, inhibiting initial T-
cell activation in the lymph nodes, preventing binding of
T cells to endothelial cells, blocking trafficking of T cells
from the circulation into psoriatic skin and preventing
reactivation of T cells in the dermal and epidermal layers
(fig. 3). By inhibiting these processes, efalizumab may
ultimately prevent keratinocyte proliferation and abnor-
mal keratinocyte differentiation from occurring, thus
blocking the development of the hallmark characteristics
of psoriasis. Data from the phase I/II trials consistently
demonstrated that efalizumab provides rapid, specific
and reversible inhibition of CD11a on T lymphocytes
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[45–48]. Efalizumab has undergone extensive clinical
testing, in more than 13 clinical trials involving more than
2,700 patients with moderate to severe chronic plaque
psoriasis treated to date.
Efalizumab Pharmacokinetics, Pharmacodynamics
and Histological Improvement
Intravenous Administration
Three phase I and II studies investigated the pharma-
codynamic properties of efalizumab, either as a single
intravenous dose of 0.03–10 mg/kg [45, 49] or repeated
weekly administration of 0.1–1 mg/kg/week for up to 8
weeks [46, 48]. Blood samples from treated patients were
subjected to fluorescence-activated cell sorter analyses in
order to assess the binding of efalizumab to lymphocytes
and to assess expression of CD11a on lymphocytes. In the
single-dose study, treatment with efalizumab caused a
rapid reduction (in less than 24 h) in the level of CD11a
expression on T cells, to approximately 25% of pretreat-
ment levels. Circulating concentrations of efalizumab in-
creased with dose. CD11a levels on lymphocytes re-
mained suppressed as long as efalizumab was present in
the circulation. Following clearance of efalizumab from
the circulation, CD11a expression returned to normal
within 7–10 days thereafter. No depletion of circulating
lymphocytes was observed. The relationship between cir-
culating levels of efalizumab and CD11a expression on
peripheral blood T cells was described via a CD11a-recep-
tor-mediated clearance model [49]. Doses above 0.3 mg/
kg were required for the full pharmacodynamic effect. A
small increase in total white blood cell (WBC) count
occurred approximately 8 h after efalizumab administra-
tion, and circulating lymphocyte counts were increased by
day 7. Following multiple weekly doses, circulating lym-
phocytes remained elevated but did not increase further
during continuous dosing with efalizumab and returned
to baseline following clearance of efalizumab. No long-
term treatment effects were observed on the proportion of
T cells, B cells and natural killer (NK) cells or on the ratio
of CD4+ and CD8+ T-cell subtypes. Furthermore, T-cell
CD11a rapidly recovered following plasma clearance of
efalizumab. All patients retained humoral immunity.
Histological analysis of psoriasis lesions from patients
in the 3 studies showed consistent reductions in epider-
mal thickness following efalizumab administration [45,
46, 48]. In patients who received repeated weekly doses of
0.3 mg/kg i.v. efalizumab, the number of T cells in the
dermis and epidermis was reduced by greater than 50%
on day 28 [46, 48]. Furthermore, on day 28 the vast
majority of patients demonstrated no detectable CD11a
binding sites in lesional skin [46]. In all 3 studies, efalizu-
mab administration resulted in a reduction in keratin 16
expression in lesional skin. Regenerative epidermal dif-
ferentiation is marked by synthesis of keratin 16 in supra-
basal keratinocytes, whereas in homoeostatic differentia-
tion (normal skin) it is not synthesized. The reduction in
keratin 16 is therefore indicative of disease resolution.
Keratinocyte ICAM-1 levels were also reduced following
efalizumab exposure, providing an indirect indication of
reduced cytokine production by T cells in the skin. At a
dose of 0.6 mg/kg i.v. weekly, efalizumab produced plas-
ma concentrations of approximately 5 Ìg/ml and main-
tained down-modulation as well as complete saturation of
CD11a binding sites on circulating and plaque T cells.
Together, the clinical, histological and pharmacodynamic
data from these studies demonstrated that by reducing the
available CD11a on circulating and cutaneous T cells,
efalizumab can halt the inflammatory process and patho-
logical hyperplasia that are the hallmarks of psoriasis.
Subcutaneous Administration
Three phase I open-label studies investigated pharma-
codynamic parameters following subcutaneous adminis-
tration of efalizumab. In the first study, patients received
either a single dose (0.3 mg/kg) or 8 weekly escalating
doses (0.5–2 mg/kg) of efalizumab (study HUPS254). In
the second study, patients received 12 weekly escalating
doses (1–4 mg/kg) of efalizumab (study HUPS256). In the
third study, patients received 12 weekly doses of efalizu-
mab (1 or 2 mg/kg/week; study ACD2124g)2. Excepting a
dose difference between the intravenous and subcuta-
neous routes, in general the effects of subcutaneously
administered efalizumab on circulating lymphocytes in
these studies were similar to those previously observed
with intravenous dosing. Doses of 1 mg/kg/week or above
produced efalizumab plasma concentrations above 5 Ìg/
ml and produced a maximal pharmacodynamic effect.
Doses equal to or greater than 1 mg/kg/week were effica-
cious with no additional benefit from the 2- and 4-mg/
kg/week doses. Data from these studies demonstrated that
there was a decrease in epidermal and dermal T-cell infil-
trates in biopsies, and a clear trend for improvement over
2 Mortensen DL, Walicke PA, Kuebler P, et al: The pharmacokinetics and
pharmacodynamics of efalizumab following 12 weeks of subcutaneous treat-
ment in patients with moderate to severe plaque psoriasis in a phase I, open-
label, multi-center study. Int Invest Dermatol Meet, Miami Beach, 2003, poster
379.
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the duration of the studies3 [XOMA (US) LLC and
Genentech Inc., data on file].
Following efalizumab treatment of 1 mg/kg/week for
12 weeks4, there was a reduction in CD11a expression on
circulating T lymphocytes to approximately 15–30% of
baseline within 1–3 days of administration, and CD11a
binding sites were generally more than 95% saturated.
Additionally, CD11a expression was down-modulated,
and CD11a binding sites were saturated on B lympho-
cytes, NK cells, monocytes and neutrophils, but to a lesser
extent than that observed on T cells. Absolute counts of
circulating lymphocytes more than doubled, while levels
of monocytes and neutrophils remained stable. Consis-
tent with the increase in lymphocytes, there was an
increase in WBC count, which gradually resolved follow-
ing clearance of efalizumab from the circulation. The
increase in peripheral lymphocyte count is presumably
due to the inhibition of binding between LFA-1 on lym-
phocytes and ICAM-1 on endothelial cells, thereby block-
ing trafficking of lymphocytes into the skin and into other
organs. Peripheral blood lymphocyte counts, CD11a ex-
pression and available CD11a binding sites returned to
pretreatment levels approximately 6 weeks following the
final dose of efalizumab, indicating that the pharmacody-
namic effects of efalizumab are reversible.
A mechanism of action substudy following treatment
with 2 mg/kg/week efalizumab (study ACD2142g)5 dem-
onstrated that efalizumab markedly reduced anti-CD3-
mediated T-cell activation and that this effect was revers-
ible following efalizumab clearance. Efalizumab treat-
ment also resulted in a marked increase in the blood of
CD8+ memory cells, a T-cell population that is selectively
increased in psoriatic lesions, suggesting retrafficking or
blocked tissue entry of a disease-relevant population in
psoriasis. Naı¨ve, but not effector, CD8+ T cells were also
increased in the blood, consistent with reduced entry into
lymph nodes. Fluorescence-activated cell sorter analyses
of peripheral blood mononuclear cells confirmed the
down-modulation of CD11a and CD18, the ·- and ß-
chains of LFA-1, on CD3+ cells. In addition, other adhe-
3 Gottlieb AB, Hamilton TK, Walicke PA, Li N, Joshi A, Garovoy M, Gor-
don KB: Efficacy, safety, and pharmacokinetic outcomes observed in patients
with plaque psoriasis during long-term efalizumab therapy: Results from an
open-label trial. Int Invest Dermatol Meet, Miami Beach, 2003, poster 1247.
4 Mortensen DL, et al: Int Invest Dermatol Meet, Miami Beach, 2003, poster
379.
5 Vugmeyster Y, Howell K, Kikuchi T, et al: Efalizumab modulates an array
of adhesion-related and activation-controlling surface protein on T lympho-
cytes and inhibits anti-CD3-induced T-cell activation in adults with moderate
to severe psoriasis. Int Invest Dermatol Meet, Miami Beach, 2003, poster 47.
sion molecules including very late antigen 4, ß7-integrin
and to some extent CD11b and L-selectin were also down-
regulated. However, CD11c, CD44 and cutaneous lym-
phocyte antigen were not down-regulated. The down-
modulation of these adhesion molecules likely contributes
to the anti-adhesive effect of efalizumab. A number of in
vitro studies have characterized the multiple effects of
efalizumab. Experiments with human umbilical vein en-
dothelial cells (HUVECs) in vitro have demonstrated that
efalizumab inhibits transendothelial trafficking of T cells
in a concentration-dependent manner (fig. 4)6, consistent
with the hypothesis that efalizumab inhibits trafficking of
T cells from blood vessels into the skin. Efalizumab also
inhibits binding of the human Jurkat T cells to normal
human keratinocytes [44], inhibits lymphocyte prolifera-
tion in a mixed lymphocyte reactions assay and binds to
lymphocytes at therapeutic concentrations achieved in
the phase III studies. Collectively, these data indicate that
efalizumab is a promising anti-adhesion antibody for the
treatment of psoriasis [50].
Results of a histological analysis of lesional tissue
(study HUPS254) indicated a significant decrease in
mean epidermal thickness in the majority of efalizumab-
treated patients with a mean decrease in epidermal thick-
ness of 22 and 40% on days 28 and 56, respectively
[Genentech Inc., data on file]. Additionally, on day 28
mean T-cell counts decreased by 44 and 52% in the epi-
dermis and dermis, respectively, and by 63% in both the
epidermis and dermis on day 56. A reduction in CD11a
binding sites was observed in all patients on day 56, with
complete blockade observed in 46% of patients. Thirty-
five percent of patients exhibited greatly reduced keratin
16 expression in suprabasal keratinocytes on day 56, indi-
cating normalization of keratinocyte maturation and
differentiation. The histological responses following 12
weeks of efalizumab treatment from an additional study
(study HUPS256) supported these findings [Genentech
Inc., data on file]. On day 84, the mean decrease in epider-
mal thickness was 48%. The mean decrease in epidermal
and dermal T-cell counts was 78 and 70%, respectively,
and complete CD11a blockade was observed in 82% of
patients. Forty-six percent of patients had no expression
of keratin 16 in suprabasal keratinocytes, indicating com-
plete resolution of psoriatic disease, and 39% of patients
did not express ICAM-1.
6 Lowe J, Stefanich E, Rangell L, Pippig S: Efalizumab (anti-CD11a) inhibits
transendothelial migration of T cells. Poster Soc Invest Dermatol Meet, Los
Angeles, 2002.
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Fig. 4. Inhibition of T-cell transendothelial trafficking with efalizu-
mab. Activated human T cells were pre-incubated in the absence and
presence of B10 Ìg/ml efalizumab and added to the HUVEC-coated
upper well of a transwell assay system. The chemokine rhuSDF-1
·/PBSF was added to the lower well, and the T cells were allowed to
transmigrate for 2.5 h. Shown are scanning electron microscopy illus-
trations of HUVEC-coated wells with T cells that had not been (a) or
had been (b) pre-incubated with efalizumab. Photos a and b demon-
strate that more T cells adhered to HUVECs in the absence than in
the presence of 10 Ìg/ml efalizumab. Whereas T cells spread out on
HUVECs in the absence of efalizumab (a), most cells retained their
round shape in the presence of efalizumab (b).
A phase III randomized, double-blind, placebo-con-
trolled multicentre clinical trial (ACD2390g) investigated
the repeated weekly administration of subcutaneous efali-
zumab (1 mg/kg/week) [C.L. Leonardi, unpubl. data].
Pharmacodynamic assessment in patients treated in this
phase III study showed results similar to previous phase I
studies with efalizumab. There was a reduction in CD11a
expression on circulating T lymphocytes to approximately
15–30% of baseline, and CD11a binding sites were gener-
ally more than 95% saturated. Mean leucocyte counts
increased 40% from baseline, and mean lymphocyte pro-
portions increased 60% from baseline, all remaining with-
in the normal range. Monocyte and neutrophil propor-
tions showed little change, and there was no depletion of
any WBC population during efalizumab therapy.
Preliminary results are available from an ongoing
open-label extended treatment trial in which patients
received subcutaneous efalizumab (2 mg/kg/week) for 12
weeks, followed by up to 33 months of maintenance thera-
py with efalizumab (1 mg/kg/week, dose increased to 2–
4 mg/kg/week as necessary), for patients who achieved at
least 50% improvement in the Psoriasis Area and Severity
Index (PASI), or a static Physician Global Assessment
(sPGA) rating of clear, minimal or mild [47]. Pharmaco-
kinetic analysis of each 12-week treatment period for up
to 15 months revealed no evidence of additional efalizu-
mab accumulation or alteration of the pharmacokinetic
profile during long-term treatment.
Efalizumab Provides Clinical Efficacy and Is Well
Tolerated in Patients with Moderate to Severe Chronic
Plaque Psoriasis
Multiple phase III studies conducted in approximately
1,650 patients have determined the efficacy and safety of
efalizumab for the treatment of moderate to severe
chronic plaque psoriasis [51, 52]. In a pooled analysis of
the first 12 weeks of therapy for 3 trials, significantly more
efalizumab-treated patients achieved a 675% decrease in
the PASI (PASI-75) and PASI-50 compared to placebo.
Significantly more efalizumab-treated patients demon-
strated improvement on all efficacy end points relative to
placebo7. Consistent with the time frame of T-cell modu-
lation, efalizumab provided rapid improvement in pso-
riasis, with a significantly greater percent PASI improve-
ment versus placebo observed after only 2 weeks of treat-
ment (p ! 0.0001).
7 Ouellet JP, Toth DP, Gratton D: Efalizumab provides rapid onset of clini-
cal benefit in patients with moderate to severe plaque psoriasis (abstract). J Eur
Acad Dermatol Venereol 2003;17:371.
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Adverse events were generally mild to moderate. The
most frequently reported events were acute adverse
events (predefined during the trials as headache, chills,
nausea, fever, myalgia and vomiting that occurred on the
day of the dose or on either of 2 days following the dose)
following the first 1 or 2 injections of efalizumab. By the
third and all subsequent doses, the incidence was compa-
rable between the efalizumab and placebo groups. Acute
adverse events were not treatment limiting, with less than
1% of patients discontinuing efalizumab due to such
events. Efalizumab was not associated with T-cell deple-
tion, increased rate of infection or malignancy, or hepato-
toxicity or nephrotoxicity8. During the efalizumab clini-
cal trials programme, 8 of 2,762 patients (0.3%) devel-
oped thrombocytopenia; therefore, platelet monitoring is
recommended. As worsening of psoriasis or new morphol-
ogies may occur during or more commonly following efal-
izumab discontinuation, appropriate psoriasis treatment
is recommended.
Conclusion
The rapid expansion in knowledge of the immuno-
pathogenesis of psoriasis has led to the development of
targeted biological agents, offering much hope for im-
proved therapies for this incurable skin disease. Some bio-
logical agents in development for psoriasis are single-
target agents that may not necessarily lead to a significant
clinical improvement [53]. Agents such as efalizumab,
which target multiple stages in the psoriasis disease pro-
cess, may prove to be more effective. Efalizumab targets
psoriasis pathogenesis at multiple levels, inhibiting T-cell
activation in the lymph nodes and binding of T cells to
endothelial cells, blocking trafficking of T cells from the
circulation into the skin, and preventing reactivation of
T cells in the dermal and epidermal tissues.
Consistent with its proposed mechanism of action,
efalizumab causes rapid down-modulation of CD11a and
saturation of CD11a binding sites on the surface of circu-
lating T lymphocytes, as well as in the dermis and epider-
mis of psoriatic lesions. This is accompanied by an
increase in the level of circulating lymphocytes, remain-
ing within normal limits, and a decrease in T-cell number
in the dermis and epidermis, most likely reflecting a
reduction in T-cell trafficking into the skin. The reduction
in keratin 16 and ICAM-1 expression in keratinocytes
suggests that efalizumab can reverse the histological evi-
dence of inflammation and epidermal hyperplasia. These
effects of efalizumab on circulating T cells and skin histol-
ogy are accompanied by significant clinical improve-
ments on multiple efficacy measures (PASI, sPGA). No
depletion of lymphocytes has been reported with repeated
efalizumab use, and any observed elevation in WBC sub-
populations was fully reversible, with a return to pretreat-
ment levels 7–10 days following clearance of efalizumab
from the circulation. Several ongoing studies are investi-
gating the long-term pharmacodynamic and histological
effects of efalizumab following continuous repeated ad-
ministration. Preliminary results from these studies indi-
cate that efalizumab provides continuous control of pso-
riasis symptoms without an increased risk of toxicity9.
Collectively, these data indicate that efalizumab may be
an important option for dermatologists seeking to provide
a well-tolerated and effective treatment modality for their
patients with moderate to severe chronic plaque psoria-
sis.
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